Oncoloxía médica

2022

1. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

   Clinical Cancer Research, Vol. 28, Núm. 1, pp. 106-115

2. A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

   Journal of Visualized Experiments, Vol. 2022, Núm. 187

3. A catalog of numerical centrosome defects in epithelial ovarian cancers

   EMBO Molecular Medicine, Vol. 14, Núm. 9

4. A genome-wide cell-free DNA methylation analysis identifies an episignature associated with metastatic luminal B breast cancer

   Frontiers in Cell and Developmental Biology, Vol. 10

5. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

   European Journal of Cancer, Vol. 175, pp. 110-119

6. A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)

   European Journal of Cancer, Vol. 177, pp. 154-163

7. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

   Annals of Oncology, Vol. 33, Núm. 2, pp. 181-192

8. Advances of Genomic Medicine in Psoriatic Arthritis

   Journal of Personalized Medicine, Vol. 12, Núm. 1

9. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

   Oncotarget, Vol. 13, Núm. 1, pp. 812-827

10. Bioactive injectable hydrogels for on demand molecule/cell delivery and for tissue regeneration in the central nervous system

    Acta Biomaterialia, Vol. 140, pp. 88-101

11. Caspase 3 and Cleaved Caspase 3 Expression in Tumorogenesis and Its Correlations with Prognosis in Head and Neck Cancer: A Systematic Review and Meta-Analysis

    International Journal of Molecular Sciences, Vol. 23, Núm. 19

12. Circulating Cancer Associated Macrophage-like Cells as a Potential New Prognostic Marker in Pancreatic Ductal Adenocarcinoma

    Biomedicines, Vol. 10, Núm. 11

13. Circulating Proteins Associated with Response and Resistance to Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer

    Cancers, Vol. 14, Núm. 4

14. Circulating tumor cell-blood cell crosstalk: Biology and clinical relevance

    Cell Reports, Vol. 40, Núm. 9

15. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

16. Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study

    Cancers, Vol. 14, Núm. 19

17. Clinical significance of baseline Pan-Immune-Inflammation Value and its dynamics in metastatic colorectal cancer patients under first-line chemotherapy

    Scientific Reports, Vol. 12, Núm. 1

18. Comparative analysis of capture methods for genomic profiling of circulating tumor cells in colorectal cancer

    Genomics, Vol. 114, Núm. 6

19. Consentimiento informado en procesos compartidos

    Cuadernos de bioética, Vol. 33, Núm. 108, pp. 149-156

20. Controlled Liposome Delivery from Chitosan-Based Thermosensitive Hydrogel for Regenerative Medicine

    International Journal of Molecular Sciences, Vol. 23, Núm. 2